<?xml version="1.0" encoding="UTF-8"?>
<document id="DDI-DrugBank.d31">
    <sentence id="DDI-DrugBank.d31.s0" text="MAO inhibitors should be used with caution in patients receiving hydralazine.">
        <entity id="DDI-DrugBank.d31.s0.e0" charOffset="0-13"
            type="group" text="MAO inhibitors"/>
        <entity id="DDI-DrugBank.d31.s0.e1" charOffset="65-75"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s0.d0" e1="DDI-DrugBank.d31.s0.e0"
            e2="DDI-DrugBank.d31.s0.e1" type="advise"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s1" text="When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.">
        <entity id="DDI-DrugBank.d31.s1.e0" charOffset="27-48"
            type="group" text="antihypertensive drugs"/>
        <entity id="DDI-DrugBank.d31.s1.e1" charOffset="59-67"
            type="drug" text="diazoxide"/>
        <entity id="DDI-DrugBank.d31.s1.e2" charOffset="99-109"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s1.d0" e1="DDI-DrugBank.d31.s1.e0"
            e2="DDI-DrugBank.d31.s1.e1" type="effect"/>
        <ddi id="DDI-DrugBank.d31.s1.d1" e1="DDI-DrugBank.d31.s1.e0"
            e2="DDI-DrugBank.d31.s1.e2" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s2" text="Profound hypotensive episodes may occur when diazoxide infection and hydralazine are used concomitantly.">
        <entity id="DDI-DrugBank.d31.s2.e0" charOffset="45-53"
            type="drug" text="diazoxide"/>
        <entity id="DDI-DrugBank.d31.s2.e1" charOffset="69-79"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s2.d0" e1="DDI-DrugBank.d31.s2.e0"
            e2="DDI-DrugBank.d31.s2.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s3" text="Beta-blockers (metoprolol, propranolol) serum concentrations and pharmacologic effects may be increased.">
        <entity id="DDI-DrugBank.d31.s3.e0" charOffset="0-12"
            type="group" text="Beta-blockers"/>
        <entity id="DDI-DrugBank.d31.s3.e1" charOffset="15-24"
            type="drug" text="metoprolol"/>
        <entity id="DDI-DrugBank.d31.s3.e2" charOffset="27-37"
            type="drug" text="propranolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s4" text="Monitor cardiovascular status."/>
    <sentence id="DDI-DrugBank.d31.s5" text="Propranolol increases hydralazines serum concentrations.">
        <entity id="DDI-DrugBank.d31.s5.e0" charOffset="0-10"
            type="drug" text="Propranolol"/>
        <entity id="DDI-DrugBank.d31.s5.e1" charOffset="22-32"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s5.d0" e1="DDI-DrugBank.d31.s5.e0"
            e2="DDI-DrugBank.d31.s5.e1" type="mechanism"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s6" text="Acebutolol, atenolol, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.">
        <entity id="DDI-DrugBank.d31.s6.e0" charOffset="0-9" type="drug" text="Acebutolol"/>
        <entity id="DDI-DrugBank.d31.s6.e1" charOffset="12-19"
            type="drug" text="atenolol"/>
        <entity id="DDI-DrugBank.d31.s6.e2" charOffset="26-32"
            type="drug" text="nadolol"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s7" text="NSAIDs may decrease the hemodynamic effects of hydralazine;">
        <entity id="DDI-DrugBank.d31.s7.e0" charOffset="0-5"
            type="group" text="NSAIDs"/>
        <entity id="DDI-DrugBank.d31.s7.e1" charOffset="47-57"
            type="drug" text="hydralazine"/>
        <ddi id="DDI-DrugBank.d31.s7.d0" e1="DDI-DrugBank.d31.s7.e0"
            e2="DDI-DrugBank.d31.s7.e1" type="effect"/>
    </sentence>
    <sentence id="DDI-DrugBank.d31.s8" text="avoid use if possible or closely monitor cardiovascular status at the end of drug interactions"/>
</document>
